Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mylan CEO Heather Bresch On How Mylan Is Different Than Teva

Jan 18 2018

• By Jessica Merrill

Related Content

J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly

Jan 09 2018

Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA

Oct 10 2017

Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce

Dec 14 2017

Generic Manufacturers Try To Up Their Game As US Pressure Persists

Jun 16 2017

Mylan Insists Complex Generics Strategy Is Poised To Deliver

Nov 06 2017

Mylan Clears Runway For US Herceptin Biosimilar Launch

Mar 13 2017

Are Theravance And Mylan's US COPD Chances Bigger Than First Thought?

Jul 24 2017

EpiPen's Swollen Price May Trigger Patient Assistance Program Probes

Aug 24 2016

Related Companies

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

Biocon, Ltd.

Roche Holding AG

GSK plc

Amgen, Inc.

Theravance Biopharma Inc.

Additional Topics

Generic Drugs Biosimilars Business Strategies Commercial Companies BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window